FDAnews Drug Daily Bulletin
Pharmaceuticals / Commercial Operations

Sloan Kettering CEO to Step Down From Merck Board

Oct. 11, 2018

Memorial Sloan Kettering Cancer Center CEO Craig B. Thompson will resign from the board of Merck amid controversy over his financial relationship with the drugmaker.

Thompson has served on Merck’s board since 2008 and the board of research assistance company Charles River Laboratories since 2013. He will step down from both.

Company financial filings revealed Merck paid Thompson $300,000 in 2017. Thompson said Memorial Sloan Kettering would conduct an analysis to address concerns over financial ties between the hospital and drug companies.

View today's stories